New lipid-lowering drugs: an update

摘要: SUMMARY Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. Statins form the basis of care but are not able treat all aspects dyslipidaemia. Many novel therapeutic compounds being developed. These include additional therapeutics for low-density lipoprotein cholesterol, example, thyroid mimetics (thyroid receptor beta-agonists), antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase-1 high-density cholesterol (HDL-C), mimetic peptides; HDL delipidation strategies ester modulators inflammation, phospholipase inhibitors. Gene therapy specific rare disorders, lipase deficiency using alipogene tiparvovec also in clinical trials. Lipid-lowering drugs likely prove fast-developing area treatments possible synergies exist between new treatment atherosclerosis.